Skip to content

Replimune Group REPL Current maturities of long-term debt

Current maturities of long-term debt at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Incyte logo
IncyteINCY
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's current maturities of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's current maturities of long-term debt?
Replimune Group (REPL) reported current maturities of long-term debt of $2.86M in Q4 2025.
How has Replimune Group's current maturities of long-term debt changed year-over-year?
Replimune Group's current maturities of long-term debt increased by 3.0% year-over-year, from $2.78M to $2.86M.
What is the long-term trend for Replimune Group's current maturities of long-term debt?
Over 4 years (2021 to 2025), Replimune Group's current maturities of long-term debt has grown at a 3.0% compound annual growth rate (CAGR), from $2.49M to $2.8M.